Related Experiment Video

Updated: Jun 6, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects

Yufei Wang1, Guangliang Li2, Hanying Wang3

  • 1Department of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China; Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.

Breast (Edinburgh, Scotland)
|November 22, 2024
PubMed

Insights

Nectin-4 is a promising therapeutic target for breast cancer. Novel treatments like antibody-drug conjugates (ADCs) targeting Nectin-4 show potential for improved cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Nectin-4, a cell adhesion molecule, is increasingly recognized as a therapeutic target in oncology.
  • Overexpression of Nectin-4 is linked to tumor progression in various cancers, including breast cancer.

Purpose of the Study:

  • To review the role of Nectin-4 in breast cancer.
  • To discuss the therapeutic potential of Nectin-4 targeted agents.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of Nectin-4's role in breast cancer progression.
  • Evaluation of Nectin-4 targeted therapies including antibody-drug conjugates (ADCs), oncolytic viruses, photothermal therapy, and immunotherapy.

Main Results:

  • Nectin-4 is overexpressed in breast cancer and associated with tumor progression.
  • Nectin-4 targeted therapies, such as ADCs (e.g., Enfortumab vedotin for urothelial carcinoma), demonstrate promising results in early-phase clinical trials for breast cancer.
  • These targeted approaches enhance treatment efficacy and minimize off-target effects.

Conclusions:

  • Nectin-4 is a validated therapeutic target for breast cancer.
  • Nectin-4 targeted agents represent a promising future direction for breast cancer treatment.
  • Further clinical development of Nectin-4 targeted therapies is warranted.
Keywords:
Antibody drug conjugates (ADCs)Breast cancerEnfortumab vedotin (EV)Nectin-4Targeted therapy

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.2K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K